跳至主要内容
临床试验/NCT02550613
NCT02550613Unknown不适用

Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2014年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
试验地点
1
主要终点
The recurrence rate at 3 months after treatment

研究概览

简要总结

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

详细描述

This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Prior Informed Consent Form
  • At least one measurable tumor, according to RECIST version 1.
  • Age > 20 years.
  • ECOG performance status 0 or
  • Life expectancy > 3 months.
  • Confirmed Diagnosis of HCC
  • Adequate renal function (Serum creatinine ≦ 1.5 x upper limit of normal).

排除标准

  • Age <20 years old
  • Contraindication for MRI: claustrophobia or MR non-compatible devices
  • Contraindication for MR contrast medium: severe adverse reaction or impaired renal function (Cre > 2.0)
  • History of other malignancy

结局指标

主要结局

The recurrence rate at 3 months after treatment

时间窗: 3 months

次要结局

  • The overall survival after treatment(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验